Comparison of Mefenamic Acid, and Tranexamic Acid in Treatment of Hypermenorrhea

Document Type : Original Article

Authors

Abstract

Introduction: Excessive menstrual bleeding is a common complaint and each year
around 5% of 30-49 year old women have this problem. The aim of this study is to
compare the efficacy and acceptability of mefenamic acid and tranexamic acid for
treating menorrhea. Attempts have been made to choose a more effective with less
complications to treat hyper menorrhea.
Materials and Methods: This study is a control trial study and the setting is Shahid
Sedugh University, department of obstetrics and gynecology ,Yazd in 2001-2005.
75 women with excessive uterine bleeding (hyper menorrhea) were under treatment
for five days from day 1 of menses during three consecutive menstrual periods. 36
patients were randomized to take mefenamic acid 500 mg, Tid; and 39 patientsto take
500 mg tranexamic acid, Qid.
Menstrual loss was measured in three control menstrual periods and three menstrual
periods during treatment. Duration of bleeding patient's estimated blood loss, sanitary
towel usage and unwanted events were also taken into consideration.
Results: mefenamic acid reduced blood loss by 20% and tranexamic acid reduced
blood loss by 50% (P=0.001). Duration of bleeding was not different in patients
treated with mefenamic acid and tranexamic acid.
Conclusions: Tranexamic acid given during menstruation is a safe and highly
effective treatment for excessive bleeding. Patients with dysfunctional uterine
bleeding should be offered medical treatment with tranexamic acid before a decision
is made about surgery. 

Keywords

References

1. Barnard K, Frayne SM, Skinner KM, Sullivan LM. Health status among women with
menstrual symptoms. J Womens Health.2003 Nov;12(9):911-9.
2. Duckitt K, Menorrhagia. Clin Evid. 2002 Dec;(8):1934-50.
3. SOGC clinical guidelines. Hysterectomy J Obstet Gynaecol Can. 2002 Jan;24(1):37-61.
4. Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins in pathology of the
endometrium Reproduction. 2003 Nov;126(5):559-67.
5. Sakara H, Ampraiwan C, Sukanya C, Anucha T, Saranya R. Coagulation defects in thai
adolescents with menorrhagia. J Thrombosis Haemostasis 2005;3(Suppl1).
6. Ann Rosenfeld Jo. MD, Treatment Decisions in the Management of Menorrhagia MJA
(The Medical Journal of Australia) 1996 (165) 510-514.
7. Oehler MK. Menorrhagia: an update. Acta Obstet Gynecol Scand. 2003 May;82 (5):405-
22.
8. Edlund M, Blomback M, He S. On the correlation between local fibrinolytic activity in
menstrual fluid and total blood loss during menstruation and effects of desmopressin.
Blood Coagul Fibrinolysis. 2003 Sep; 14(6):593-8.
9. Edlund M. Fibrinolysis in menstrual blood in healthy and in women with menorrhagia. J
Thrombosis Haemostasis. 2001 Jul.
10. Jabbour HN .Cyclooxygenase enzymes and prostaglandins in pathology of the Sales.
Reproduction. 2003 Nov; 126(5) :559-6
11. Haynes PJ, Flint AP, Hodgson H, Anderson AB, Dray F. Turnbull AC. Studies in
menorrhagia: (a) mefenamic acid, (b) endometrial prostaglandin concentrations Int J
Gynecol Obstet. 1980 May-Jun;17(6):567-72.
12. Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long-term treatment of
menorrhagia with mefenamic acid. Obstet Gynecol. 1983 Jan;61(1):109-12.
13. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of
menorrhagia. Drugs. 2003;63(13):
14. Aegerter Ch, Friess D, Alberio L. Menorrhagia caused by severe hereditary factor VII
deficiency. Hamostaseologie. 2003 Aug;23(3):99-102.
15. L Michael Kettel, MD Abnormal Uterine Bleeding Best Practice of Medicine.
February 2002
16. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M. Menorrhagia I:
measured blood loss, clinical features, and outcome in women with heavy periods: a
survey with follow-up data. Am J Obstet Gynecol. 2004; 190(5):1216-23.
17. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and
danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol 1989;(96)
:840-4.
18. Cameron IT, Haining R, Linsden M-A, Thomas VR, Smith SK. The effects of
mefenamic acid and norethisterone on measured menstrual blood loss. Obstet
Gynecol 1990, (76):85-8.
19. Ann Rosenfeld Jo, MD, Quillen College of Medicine Treatment Decisions in the
Management of Menorrhagia General Medicine .1999;1(2):
20. Hall P, MacLachlin N, Thorn N. Control of menorrhagia by the cyclo-oxygenase
inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987;
94:554-8.
21. Carl Wood E, Menorrhagia: a clinical update. Med J Australia. 1996; 165:510-514.
22. Lethaby A, FarquharC. Treatments for heavy menstrual bleeding.BMJ. 2003 Nov 29;
327(7426):1243-4. 
 
23. Kawaja M, Scully MF, Barrett B, Walsh M. An evaluation of existing measurement
methods in assessing menstrual blood loss in women with hereditary bleeding disorders.
J Thrombosis Haemostasis. 2003 Jul ;( 1).
24. Reid PC, Virtanen-Kari SLuton, Dunstable NHS, Luton, UK. Randomised comparative
trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of
idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual
blood loss and pictorial blood loss assessment charts. BJOG. 2005; 112(8):1121-5.
25. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid
and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995
;( 102): 401-6.
26. Rybo G. Tranexamic acid therapy is effective treatment in heavy menstrual bleeding.
Clinical Update on Safety Therapeutic Advances 1991;(4):1-8.
27. Korsen N, Doyle LRoutine diagnostic hysteroscopy not necessary for premenopausal
women with abnormal uterine bleeding.J Fam Pract. 2002 Nov; 51(11):920.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 9, Issue 2 - Serial Number 2
September 2007
Pages 17-22

Files

Share

How to cite

Statistics